Budget Fuels Pharma Growth, But Generic Access Stalls

The recent Union Budget has outlined a plan to strengthen India's pharmaceutical industry through planned investments in innovation and infrastructure. This strategy aims to improve its global position. However, the promise of lower costs through generic medicines is limited by several issues that prevent them from reaching most people. The projected growth of India's generic drug market to $53.5 billion by 2034 contrasts sharply with ongoing high out-of-pocket healthcare costs, showing a gap between national goals and real-world healthcare costs.

Budget Boosts Pharma, But Market Shows Mixed Signals

Significant funding, including the ₹10,000 crore 'Biopharma Shakti' initiative over five years, has been allocated. This has been met with a mixed market reaction, with the NIFTY Pharma Index showing some positive movement after budget announcements in early 2026, indicating investor confidence in the government's commitment. This strategic push aims to make India a global hub for biologics and biosimilars, moving focus from high-volume traditional generics. However, recent market data from May 2026 shows sector-wide volatility. Some major generic players are dealing with lost sales and pricing pressures, highlighting that economic conditions and individual drug lifecycles can temper policy optimism. India's pharmaceutical exports are significant, with generics making up about 70% of industry revenue and supplying a large part of global demand, especially to regulated markets like the US and Europe.

Generics Dilemma: Branded Drugs Dominate Domestic Market

Despite India's reputation as the 'pharmacy of the world,' the domestic market has internal issues. While the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) aims to provide quality generics at 50-90% lower costs, saving citizens an estimated ₹5,000 crore annually, its reach is limited. Key problems include too few Jan Aushadhi Kendras, limited drug variety, and inconsistent availability. More fundamentally, the market strongly favors 'branded generics'—generic drugs sold under a brand name, often 10-12 times more expensive than unbranded equivalents. This dominance, accounting for 87% of domestic drug consumption, greatly weakens government efforts to control costs. Doctors' prescribing habits are key, with many favoring branded medicines due to beliefs about quality, incentives from drug companies, and patient trust, even while acknowledging generics' cost benefits. Pharmacists are generally more willing to dispense generics. The significant rise in per capita healthcare spending, reaching $79.52 in 2022, with medicines making up a large part of out-of-pocket spending, highlights the urgent need for generics to be used more widely.

Regulatory Hurdles and Physician Habits Slow Generic Adoption

Rule 65(11)(a) of the Drugs and Cosmetics Rules, 1945, which prevents pharmacists from substituting prescribed brand-name drugs with generics, is a major regulatory obstacle, giving doctors more control over prescriptions. Fitch Ratings analysts note that making generic prescription rules work in India faces major execution challenges. This is partly because drug quality standards are less strict than in places like the U.S., potentially leading to differences in drug quality and effectiveness between manufacturers. The rise of branded generics, fueled by aggressive marketing and doctor relationships, means a significant drop in branded generic sales could hurt the profits of major Indian drug companies like Sun Pharma, Cipla, Dr. Reddy's Laboratories, and Aurobindo Pharma, even with their strong global generic businesses. Healthcare spending of $79.52 per person is expected to rise, especially with more chronic diseases, requiring more affordable treatments. The government aims to expand the PMBJP to all districts by 2024, adding more medicines and surgical items, which poses complex supply chain challenges.

Outlook: Innovation Push vs. Affordable Medicine Access

Looking ahead, India's pharmaceutical sector is set for continued growth, with the generic drugs market expected to expand significantly. The government's focus is shifting to high-value biologics and biosimilars, to reduce import reliance and boost R&D. While this diversification is promising, getting affordable, unbranded generics widely used depends on solving key systemic problems. These include boosting public awareness, making Jan Aushadhi Kendras' supply chains more reliable, and creating an environment that encourages doctors and pharmacists to prescribe generics. Without strong enforcement and a market shift away from branded generics, the budget's goal of lowering healthcare costs for ordinary citizens will likely remain just that—a goal.